September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics with data analysis and chemical interpretation for the study.
The research is part of the INTERBIO-21st Study by the Oxford Maternal & Perinatal Health Institute (OMPHI) and Nuffield Department of Women’s & Reproductive Health, which aims to improve the phenotypic characterization of the fetal growth restriction/small for gestational age (FGR/SGA) and preterm birth syndromes at the molecular, biochemical, and clinical level.
Sapient performed complex non-targeted mass spectrometry analysis of thousands of circulating small molecule biomarkers in over 3,500 biological samples obtained from mothers early during pregnancy, enrolled as part of the INTERBIO-21st Study. This analysis was supported by a grant from the Bill & Melinda Gates Foundation. The data generated identified specific patterns of lipid metabolites that closely tracked with fetal growth trajectories and point to potential mechanisms that regulate fetal growth during development. The lipid signatures could also potentially represent a biomarker of metabolic or immunological differences between maternal-fetal dyads, including factors such as pre-pregnancy BMI or maternal nutritional status.
“We are very excited to support the INTERBIO-21st Study team in its mission to understand fetal development and improve maternal-child health around the world,” said Mohit Jain, MD, PhD, Founder and CEO of Sapient. “Population-scale human studies have tremendous power to unlock the underpinnings of human health and disease, and Sapient’s technologies and biocomputational approaches provide a key to this knowledge. We are looking forward to our continued work supporting these international efforts to improve human health.”
The full paper, entitled “Fetal abdominal growth trajectories, associated with maternal metabolite signatures early in pregnancy, are footprints for childhood growth and adiposity”, can be accessed here.
Sapient is an end-to-end biomarker discovery organization dedicated to accelerating the mapping of circulating chemistries in humans through rapid, large-scale small molecule biomarker profiling. Its platform combines next-generation mass spectrometry technologies capable of assaying tens of thousands of small molecule biomarkers in human biosamples, advanced biocomputational learning, and a proprietary Human Biology Database with extensive data from several hundred thousand biosamples. Together these approaches enable rapid discovery and validation of circulating biomarkers of health, disease, and drug responsiveness at unprecedented speed and scale. For more information, visit sapient.bio.
Head of Marketing, Sapient
University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics… Read More
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating… Read More
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022—San Diego, CA—Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a… Read More
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one… Read More
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to… Read More
Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area Lyme Foundation’s 2021 Impact Update report for its collaboration with the Foundation aimed at establishing new diagnostics for persistent Lyme disease (PLD). The report… Read More
San Diego, CA—Sapient, a full-service bioanalytical research organization transforming the efficiency of biomarker discovery for pharmaceutical and biotechnology sponsors, announced that Philip Worboys, Ph.D. has joined its leadership team as Head of Translational Science. In this role, Dr. Worboys will work with Sapient’s cross-functional teams to develop and execute scientifically… Read More